Concepedia

Mark W. Ledeboer

MW

19

Publications

1.2K

Citations

19

H-Index

1996

Active since

Affiliations

Vertex Pharmaceuticals (United States)(Current)

Scripps Research Institute

Goldfinch Bio (United States)

Vertex Pharmaceuticals (Canada)

Mark W. Ledeboer is an author at Vertex Pharmaceuticals (United States) specializing in medicine, drug discovery, and pharmacology.

ORCID

Top concepts

Publications per year

1996–2022

19

Publications

19

Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2

Michael P. Clark, Mark W. Ledeboer, Ioana Davies et al. · Journal of Medicinal Chemistry · 2014 · 207 citations · Full text

, , +13

Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit

Randal A. Byrn, Steven J.M. Jones, Hamilton B. Bennett et al. · Antimicrobial Agents and Chemotherapy · 2014 · 185 citations · Full text

Asymmetric Reduction. A Convenient Method for the Reduction of Alkynyl Ketones

Kathlyn A. Parker, Mark W. Ledeboer · The Journal of Organic Chemistry · 1996 · 118 citations

, , +12

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock et al. · Journal of Medicinal Chemistry · 2015 · 87 citations

, , +16

Structural basis of TRPC4 regulation by calmodulin and pharmacological agents

Deivanayagabarathy Vinayagam, Dennis Quentin, Jing Yu-Strzelczyk et al. · eLife · 2020 · 66 citations · Full text

Rows per page

1–5 of 19